Innoviva (INVA) Depreciation & Amortization (CF) (2010 - 2022)
Innoviva (INVA) posted Depreciation & Amortization (CF) of $12.5 million for Q3 2022, up 248.29% on a QoQ basis from $3.6 million in Q2 2022, and up 20.54% year-over-year from $10.4 million in Q3 2021.
Innoviva (INVA) Depreciation & Amortization (CF) (2010 - 2022) Analysis & Trends
Innoviva's Depreciation & Amortization (CF) history runs 13 years deep, the most recent figure standing at $12.5 million for Q3 2022.
- Quarterly Depreciation & Amortization (CF) rose 20.54% year-over-year to $12.5 million in Q3 2022, while the trailing twelve-month figure through Jun 2023 was $12.5 million (down 28.4% YoY) and the FY2021 annual result came in at $13.8 million, changed 0.06% from the prior year.
- Depreciation & Amortization (CF) was $12.5 million for Q3 2022 at Innoviva, up from $3.6 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $12.5 million in Q3 2022 and bottomed at $3.3 million in Q3 2019.
- A 5-year average of $4.4 million and a median of $3.5 million in 2018 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2019 — Depreciation & Amortization (CF) declined 4.27% — and 2021, when it soared 199.8%.
- Innoviva's Depreciation & Amortization (CF) stood at $3.5 million in 2018, then grew by 0.17% to $3.5 million in 2019, then dropped by 0.46% to $3.5 million in 2020, then jumped by 200.06% to $10.4 million in 2021, then climbed by 20.54% to $12.5 million in 2022.
- Business Quant data shows INVA's Depreciation & Amortization (CF) at $12.5 million in Q3 2022, $3.6 million in Q2 2022, and $3.5 million in Q1 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 12.51 Mn |
| Sep 30, 2022 | 12.51 Mn |
| Jun 30, 2022 | 3.59 Mn |
| Jun 30, 2022 | 3.59 Mn |
| Mar 31, 2022 | 3.50 Mn |
| Mar 31, 2022 | 3.50 Mn |
| Sep 30, 2021 | 10.38 Mn |
| Sep 30, 2021 | 10.38 Mn |
| Jun 30, 2021 | 3.46 Mn |
| Jun 30, 2021 | 3.46 Mn |
| Mar 31, 2021 | 3.46 Mn |
| Mar 31, 2021 | 3.46 Mn |
| Dec 31, 2020 | 3.46 Mn |
| Dec 31, 2020 | 3.46 Mn |
| Sep 30, 2020 | 3.46 Mn |
| Sep 30, 2020 | 3.46 Mn |
| Jun 30, 2020 | 3.46 Mn |
| Jun 30, 2020 | 3.46 Mn |
| Mar 31, 2020 | 3.46 Mn |
| Mar 31, 2020 | 3.46 Mn |